Skip to main content
. 2007 Nov 28;7:44. doi: 10.1186/1471-230X-7-44

Table 1.

Change in concentrations of laboratory data (mean ± SD)*

Sham BDL BDL + vehicle BDL + fenofibrate
Bilirubin (mg/dl) 0.68 ± 0.17 9.05 ± 2.24a 8.98 ± 2.78a 6.02 ± 1.56a,b,c
ALT (IU/L) 45.7 ± 9.7 115.7 ± 16.5a 117.4 ± 20.2a 82.7 ± 12.0a,b,c
AST (IU/l) 78.1 ± 9.6 142.8 ± 17.8a 147.7 ± 24.0a 99.4 ± 13.6a,b,c
GGT (IU/l) 7.7 ± 2.7 37.8 ± 8.0a 34.4 ± 13.1a 26.4 ± 6.2a,b,c
ALP (IU/L) 95.9 ± 19.4 408.2 ± 42.4a 416.0 ± 62.6a 381.6 ± 36.9a,b
TBA (μmol/ml) 3.2 ± 1.2 34.3 ± 3.8a 35.7 ± 2.9a 26.7 ± 4.1a,b,c
TNF-α (pg/mL) 6.2 ± 2.57 45.7 ± 4.61a 43.8 ± 5.86a 32.7 ± 5.6a,b,c
IL-1β (pg/mL) 7.3 ± 3.9 130.3 ± 16.6a 128.3 ± 23.9a 83.2. ± 11.3a,b,c
Tissue MDA levels (nmol/mg protein) 0.5 ± 0.2 4.9 ± 1.2a 4.8 ± 0.9a 2.1 ± 0.4a,b,c

*Comparisons between groups were done by using Kruskal-Wallis test. Paired comparisons are done by using Mann-Whitney U test.

aP < 0.01 versus sham group (Mann-Whitney U after Kruskal-Wallis test)

bP < 0.01 as compared to BDL groups (Mann-Whitney U after Kruskal-Wallis test)

cP < 0.01 as compared to BDL + vehicle groups (Mann-Whitney U after Kruskal-Wallis test)

HHS Vulnerability Disclosure